Abstract
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m2/day or 150 mg/m2/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m2/day or 125 mg/m2/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Fletchner H, Fleishman SB & de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS, Brampton M & Stevens MFG (1995) Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910–913
Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJH, Calvert H, Colquhoun I, Lewis P & Brampton MH (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484–488
Brada M, Thomas DGT, Bleehen NM, Roberts JT, Senanayake F, Abram P, Lantos PL, Moss TH, Ironside JW, Whaley JB & Stenning SP (1998). Proceedings of the American Society of Clinical Oncology 17,
Brock CS, Matthews JC, Brown G, Luthra SK, Brady F, Newlands ES & Price P (1996) The kinetic behaviour of temozolomide in man. Proceedings of the American Society of Clinical Oncology 15: 475
Brock CS, Matthews JC, Brown G, Newlands ES & Price P (1997) In vivo demonstration of11C-temozolomide uptake by human recurrent high grade astrocytomas. Br J Cancer 75: 1241
Burger PC, Vogel FS, Green SB & Strike TA (1985) Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56: 1106–1111
Chamberlain MC & Kormanik PA (1998) Practical guidelines for the treatment of malignant gliomas. West J Med 168: 114–120
Fayers P, Aaronson N, Bjordal K & Sullivan M (1995). EORTC QLQ-C30 Scoring Manual, Brussels, Belgium, Quality of Life Unit, EORTC Data Centre
Fine HA, Dear KB, Loeffler JS, Black PM & Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant glioma in adults. Cancer 71: 2585–2597
Feun LG, Savaraj N & Landy HJ (1994) Drug resistance in brain tumors. J Neurooncol 20: 165–176
Forsyth PA & Cairncross JG (1996) Chemotherapy for malignant gliomas. Baillières Clin Neurol 5: 371–393
Jaeschke R, Singer J & Guyatt GH (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10: 407–415
Juniper EF, Guyatt GH, Willan A & Griffith LE (1994) Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 47: 81–87
King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5: 555–567
Kumar ARV, Renaudin J, Wilson CB, Boldrey EB, Enot KJ & Levin VA (1974) Procarbazine hydrochloride in the treatment of brain tumors. J Neurosurg 40: 365–371
Levin VA, Leibel SA & Gutin PH (1997) Neoplasms of the central nervous system. In: DeVita Jr VT, Hellman S, Rosenberg SA, (eds). Cancer Principals and Practice of Oncology, Philadelphia: Lippincott Raven 2041–2042
McComb RD & Burger PC (1985) Pathologic analysis of primary brain tumors. Neurol Clin 3: 711–728
Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH & Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287–291
Newlands ES, O’Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD & Richards PG (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236–2241
Newton HB, Junck L, Bromberg J, Page MA & Greenberg HS (1990) Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40: 1743–1746
O’Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P & Stevens MFG (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940–942
Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu M-A, Yung WKA, Brada M & Newlands E (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5: 139–150
Osoba D, Aaronson N, Zee B, Sprangers M & te Velde A (1997) Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Qual Life Res 6: 103–108
Osoba D, Rodrigues G, Myles J, Zee B & Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16: 139–144
Patel M, McCully C, Godwin K & Balis F (1995) Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proceedings of the American Society of Clinical Oncology 14: 461
Rodriguez LA, Prados M, Silver P & Levin VA (1989) Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumours. Cancer 64: 2420–2423
Stevens MFG, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, Newton C, Lunt E, Fizames C & Lavelle F (1987) Antitumor activity and pharmacokinetics in mice of 8-Carbamoyl-3-methylimidazo [5,1- d ]-1,2,3,5-tetrazin-4(3 H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846–5852
Tsang LLH, Farmer PB, Gescher A & Slack JA (1990) Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 26: 429–436
Ware JEE Jr, Kosinski M & Keller SD SF-36 Physical and Mental Health Summary Scales: A User’s Manual [Homepage of QualityMetric], [Online]. Available: http://www.qmetric.com/products/manuals/SF-36-Summary.php3 [1999, March 1]
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Yung, W., Albright, R., Olson, J. et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83, 588–593 (2000). https://doi.org/10.1054/bjoc.2000.1316
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1316
Keywords
This article is cited by
-
Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme
Metabolic Brain Disease (2023)
-
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
BMC Cancer (2022)
-
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines
NeuroMolecular Medicine (2022)
-
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults
Journal of Neuro-Oncology (2022)
-
Z-scan method to measure the nonlinear optical behavior of cells for evaluating the cytotoxic effects of chemotherapy and hyperthermia treatments
Lasers in Medical Science (2021)